The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53- independent manner in colon and breast cancer cells

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  García, María Angel ^a,b   Carrasco, Esther ^b   Aguilera, Margarita ^a   Alvarez, Pablo ^b   Rivas, Carmen ^c   Campos, Joaquin María ^d   Prados, Jose Carlos ^b   Calleja, Miguel Angel ^a   Esteban, Mariano ^c   Marchal, Juan Antonio ^b   Aránega, Antonia ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN KINASE R; PROTEIN P53; RECOMBINANT ALPHA2B INTERFERON; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF 2ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; BREAST TUMOR; COLON TUMOR; FEMALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; EIF-2 KINASE; FEMALE; FLUOROURACIL; HUMANS; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051970968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023887     Document Type: Article

References (68)

1. Ajani J, (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107: 221-231.
2. Ershler WB, (2006) Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data. Crit Rev Oncol Hematol 58: 68-78.
3. Longley DB, Harkin DP, Johnston PG, (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
4. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, et al. (2009) Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 7: e91.
5. Petak I, Tillman DM, Houghton JA, (2000) p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 6: 4432-4441.
6. Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, et al. (2003) Thymidylate synthase inhibition triggers apoptosis via caspases-8 and-9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 39: 1310-1317.
7. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269.
8. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975-990.
9. Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, et al. (2007) Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. Clin Pharmacol Ther 81: 354-361.
10. Borden EC, (2005) Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res 25: 511-527.
11. Wadler S, (1992) Back to the future: new theories on 5-fluorouracil/interferon interactions. Cancer Invest 10: 323-326.
12. Wadler S, Schwartz EL, (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473-3486.
13. Sparano JA, Wadler S, Schwartz EL, Diasio R, (1993) Clinical and pharmacological studies of interferon and chemotherapy in gastrointestinal and breast cancer. Int J Clin Pharmacol Res 13: 1-9.
14. Esteban M, Kerr IM, (1974) The synthesis of encephalomyocarditis virus polypeptides in infected L-cells and cell-free systems. Eur J Biochem 45: 567-576.
15. Sen GC, Taira H, Lengyel P, (1978) Interferon, double-stranded RNA, and protein phosphorylation. Characteristics of a double-stranded RNA-activated protein kinase system partially purified from interferon treated Ehrlich ascites tumor cells. J Biol Chem 253: 5915-5921.
16. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, et al. (2006) Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70: 1032-1060.
17. Peel AL, (2004) PKR activation in neurodegenerative disease. J Neuropathol Exp Neurol 63: 97-105.
18. Li S, Koromilas AE, (2001) Dominant negative function by an alternatively spliced form of the interferon-inducible protein kinase PKR. J Biol Chem 276: 13881-13890.
19. Murad JM, Tone LG, de Souza LR, De Lucca FL, (2005) A point mutation in the RNA-binding domain I results in decrease of PKR activation in acute lymphoblastic leukemia. Blood Cells Mol Dis 34: 1-5.
20. Shimada A, Shiota G, Miyata H, Kamahora T, Kawasaki H, et al. (1998) Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. Cancer Res 58: 4434-4438.
21. Galabru J, Hovanessian A, (1987) Autophosphorylation of the protein kinase dependent on double-stranded RNA. J Biol Chem 262: 15538-15544.
22. Rhoads RE, (1993) Regulation of eukaryotic protein synthesis by initiation factors. J Biol Chem 268: 3017-3020.
23. Kumar A, Yang YL, Flati V, Der S, Kadereit S, et al. (1997) Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J 16: 406-416.
24. Gil J, Alcami J, Esteban M, (2000) Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex. Oncogene 19: 1369-1378.
25. Hovanessian AG, Galabru J, (1987) The double-stranded RNA-dependent protein kinase is also activated by heparin. Eur J Biochem 167: 467-473.
26. Ruvolo PP, Gao F, Blalock WL, Deng X, May WS, (2001) Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J Biol Chem 276: 11754-11758.
27. Ke ZJ, Wang X, Fan Z, Luo J, (2009) Ethanol promotes thiamine deficiency-induced neuronal death: involvement of double-stranded RNA-activated protein kinase. Alcohol Clin Exp Res 33: 1097-1103.
28. Patel RC, Sen GC, (1998) PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 17: 4379-4390.
29. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, et al. (1998) Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 17: 6888-6902.
30. Gil J, Esteban M, (2000) Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 5: 107-114.
31. Gil J, Garcia MA, Esteban M, (2002) Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Lett 529: 249-255.
32. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, et al. (1995) Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 14: 6095-6106.
33. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, et al. (2001) Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 7: 1165-1176.
34. Villalobos C, Garcia-Sancho J, (1995) Capacitative Ca2+ entry contributes to the Ca2+ influx induced by thyrotropin-releasing hormone (TRH) in GH3 pituitary cells. Pflugers Arch 430: 923-935.
35. Haug K, Kravik KL, De Angelis PM, (2008) Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil. Anticancer Res 28: 583-592.
36. Brown JM, Wouters BG, (1999) Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399.
37. Yoon CH, Lee ES, Lim DS, Bae YS, (2009) PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc Natl Acad Sci U S A 106: 7852-7857.
38. Peidis P, Papadakis AI, Muaddi H, Richard S, Koromilas AE, (2011) Doxorubicin bypasses the cytoprotective effects of eIF2alpha phosphorylation and promotes PKR-mediated cell death. Cell Death Differ.
39. Tan SL, Tareen SU, Melville MW, Blakely CM, Katze MG, (2002) The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation. J Biol Chem 277: 36109-36117.
40. Saelens X, Kalai M, Vandenabeele P, (2001) Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol Chem 276: 41620-41628.
41. Pap M, Szeberenyi J, (2008) Involvement of proteolytic activation of protein kinase R in the apoptosis of PC12 pheochromocytoma cells. Cell Mol Neurobiol 28: 443-456.
42. Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, et al. (2010) Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 16: 5522-5528.
43. Holcik M, Sonenberg N, (2005) Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6: 318-327.
44. Zamanian-Daryoush M, Der SD, Williams BR, (1999) Cell cycle regulation of the double stranded RNA activated protein kinase, PKR. Oncogene 18: 315-326.
45. Patel RC, Handy I, Patel CV, (2002) Contribution of double-stranded RNA-activated protein kinase toward antiproliferative actions of heparin on vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 22: 1439-1444.
46. Dagon Y, Dovrat S, Vilchik S, Hacohen D, Shlomo G, et al. (2001) Double-stranded RNA-dependent protein kinase, PKR, down-regulates CDC2/cyclin B1 and induces apoptosis in non-transformed but not in v-mos transformed cells. Oncogene 20: 8045-8056.
47. Donze O, Deng J, Curran J, Sladek R, Picard D, et al. (2004) The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J 23: 564-571.
48. Kazemi S, Mounir Z, Baltzis D, Raven JF, Wang S, et al. (2007) A novel function of eIF2alpha kinases as inducers of the phosphoinositide-3 kinase signaling pathway. Mol Biol Cell 18: 3635-3644.
49. Deng J, Lu PD, Zhang Y, Scheuner D, Kaufman RJ, et al. (2004) Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol 24: 10161-10168.
50. Peidis P, Papadakis AI, Muaddi H, Richard S, Koromilas AE, (2011) Doxorubicin bypasses the cytoprotective effects of eIF2alpha phosphorylation and promotes PKR-mediated cell death. Cell Death Differ 18: 145-154.
51. Williams BR, (2001) Signal integration via PKR. Sci STKE 2001 pp. re2.
52. Der SD, Yang YL, Weissmann C, Williams BR, (1997) A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci U S A 94: 3279-3283.
53. Yeung MC, Liu J, Lau AS, (1996) An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci U S A 93: 12451-12455.
54. Guerra S, Lopez-Fernandez LA, Garcia MA, Zaballos A, Esteban M, (2006) Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J Biol Chem 281: 18734-18745.
55. Zhang P, Langland JO, Jacobs BL, Samuel CE, (2009) Protein kinase PKR-dependent activation of mitogen-activated protein kinases occurs through mitochondrial adapter IPS-1 and is antagonized by vaccinia virus E3L. J Virol 83: 5718-5725.
56. Wadler S, Goldman M, Lyver A, Wiernik PH, (1990) Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma. Cancer Res 50: 2056-2059.
57. Presant CA, Wolf W, Waluch V, Wiseman CL, Weitz I, et al. (2000) Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. J Clin Oncol 18: 255-261.
58. Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, et al. (2007) Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 46: 77-88.
59. Elias L, Sandoval JM, (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163: 867-874.
60. Eguchi H, Nagano H, Yamamoto H, Miyamoto A, Kondo M, et al. (2000) Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6: 2881-2890.
61. Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, et al. (2004) Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. Clin Cancer Res 10: 7884-7895.
62. Hector S, Prehn JH, (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 1795: 117-129.
63. Sorensen HT, Rothman KJ, (2010) The prognosis for research. BMJ 340: c703.
64. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, et al. (2010) Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15: 390-404.
65. Schmitz JC, Liu J, Lin X, Chen TM, Yan W, et al. (2001) Translational regulation as a novel mechanism for the development of cellular drug resistance. Cancer Metastasis Rev 20: 33-41.
66. Kudo K, Xi Y, Wang Y, Song B, Chu E, et al. (2010) Translational control analysis by translationally active RNA capture/microarray analysis (TrIP-Chip). Nucleic Acids Res 38: e104.
67. Ju J, Schmitz JC, Song B, Kudo K, Chu E, (2007) Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res 13: 4245-4251.
68. Baltzis D, Pluquet O, Papadakis AI, Kazemi S, Qu LK, et al. (2007) The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J Biol Chem 282: 31675-31687.